Biomarker Proteasome Levels Predict Response to Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients
Korde N, Dosani T, Simakova O, Mailankody S, Costello R, Roschewski M, Yuan C, Stetler-Stevenson M, Figg W, Landgren O, Maric I. Biomarker Proteasome Levels Predict Response to Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients. Blood 2014, 124: 2080. DOI: 10.1182/blood.v124.21.2080.2080.Peer-Reviewed Original ResearchIndependent data monitoring committeeMultiple myeloma patientsNon-CR groupsPlasma cellsMyeloma patientsData monitoring committeeMFI ratioCR groupCombination therapyPre-treatment bone marrow samplesResponse rateProteasome levelsMinimal residual disease statusGood partial response rateProgression-free survival dataMonitoring committeeMean fluorescence intensity ratioNovel flow cytometric assayBone marrow plasma cellsCarfilzomib-based therapyComplete response/Mean percentage declinePatient's good responsePartial response rateResidual disease status